Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Editas Medicine (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,257,881
  • Shares Outstanding, K 47,810
  • Annual Sales, $ 13,730 K
  • Annual Income, $ -120,320 K
  • 36-Month Beta 3.21
  • Price/Sales 96.26
  • Price/Cash Flow N/A
  • Price/Book 5.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.39
  • Number of Estimates 6
  • High Estimate -0.06
  • Low Estimate -0.73
  • Prior Year -0.84
  • Growth Rate Est. (year over year) +53.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.06 +4.99%
on 11/20/18
32.46 -18.95%
on 12/03/18
-2.65 (-9.15%)
since 11/16/18
3-Month
24.21 +8.67%
on 10/30/18
33.80 -22.16%
on 09/19/18
-6.51 (-19.84%)
since 09/18/18
52-Week
24.21 +8.67%
on 10/30/18
45.02 -41.56%
on 03/09/18
+1.19 (+4.74%)
since 12/18/17

Most Recent Stories

More News
Editas Medicine Names Cynthia Collins to Board of Directors

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Cynthia Collins to its Board of Directors.

EDIT : 26.31 (-4.81%)
Analysis: Positioning to Benefit within IDEXX Laboratories, Editas Medicine, Arconic, Cardtronics, Cloudera, and BMC Stock -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of IDEXX Laboratories, Inc....

ARNC : 18.70 (-2.35%)
CATM : 27.07 (+6.53%)
CLDR : 11.66 (+2.64%)
IDXX : 187.57 (+2.06%)
EDIT : 26.31 (-4.81%)
BMCH : 15.64 (+2.09%)
Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of 55.56% and 120.82%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

EDIT : 26.31 (-4.81%)
Editas: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Editas Medicine Inc. (EDIT) on Wednesday reported a loss of $15.2 million in its third quarter.

EDIT : 26.31 (-4.81%)
Editas Medicine Announces Third Quarter 2018 Results and Update

Filed IND application for EDIT-101 with FDA in October

EDIT : 26.31 (-4.81%)
5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings

There are still a number of drug/biotech companies poised to surpass third-quarter estimates.

CRSP : 29.54 (-6.46%)
BDSI : 3.27 (-4.94%)
EDIT : 26.31 (-4.81%)
REGN : 369.00 (-1.73%)
MACK : 4.00 (-1.72%)
Editas Medicine (EDIT) Gains As Market Dips: What You Should Know

In the latest trading session, Editas Medicine (EDIT) closed at $28, marking a +1.97% move from the previous day.

EDIT : 26.31 (-4.81%)
Editas Medicine to Host Conference Call Discussing Third Quarter 2018 Corporate Update and Results

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, November 7, 2018, at 5:00 p.m. ET to discuss a corporate...

EDIT : 26.31 (-4.81%)
Is a Beat in Store for Editas (EDIT) This Earnings Season?

On Editas' (EDIT) third-quarter conference call, investor focus will be on the company's progress with its proprietary genome editing platform based on CRISPR technology.

CRSP : 29.54 (-6.46%)
AGN : 146.76 (-1.06%)
EDIT : 26.31 (-4.81%)
SPRO : 6.00 (+0.17%)
Editas Medicine (EDIT) Stock Moves -0.95%: What You Should Know

Editas Medicine (EDIT) closed the most recent trading day at $25.98, moving -0.95% from the previous trading session.

EDIT : 26.31 (-4.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade EDIT with:

Business Summary

Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 29.04
1st Resistance Point 27.68
Last Price 26.31
1st Support Level 25.23
2nd Support Level 24.14

See More

52-Week High 45.02
Fibonacci 61.8% 37.07
Fibonacci 50% 34.61
Fibonacci 38.2% 32.16
Last Price 26.31
52-Week Low 24.21

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar